Azra Raza, Medical Oncologist at NewYork Presbyterian/Columbia University Medical Center offers her perspective on the current cancer landscape which contributed to shaping the Cancer MoonShot.Read More
The recent groundbreaking ceremony in Richland Township paves a way for the establishment of the Johnstown Heart and Vascular Center in the region. The collaboration with Windber hospital represents the positive impact of the medical center on the community that would now have access to basic as well as comprehensive cardiovascular care in the growing Richland region. In the future, the Windber hospital will hold clinical trials for cancer treatment, and will further connect the research institute’s science with other Cancer MoonShot 2020 efforts across the globe to improve treatments and eventually eradicate cancer.Read More
Altor BioScience Corporation (Altor), a leading developer of cancer immunotherapeutics, announced enrollment is complete for the first cohort in a Phase 1b/2 trial using ALT-803, a proprietary interleukin-15 (IL-15) superagonist protein complex, in combination with the approved anti-PD-1 antibody (Ab) nivolumab (Opdivo®; Bristol-Myers Squibb) for patients with pre-treated, advanced, or metastatic non-small cell lung cancer (NSCLC). This Investigator-Sponsored Trial is being conducted under the direction of John Wrangle, M.D., M.P.H., at the Medical University of South Carolina (MUSC).Read More
Cancer MoonShot 2020 announced the formation of the Melanoma and Sarcoma Working Group to accelerate molecular-informed immunotherapy trials and to focus on identifying the most effective, cancer-directed immunotherapy treatments for patients with melanoma and sarcoma.Read More
Cancer MoonShot 2020 announced the formation of the Head and Neck Working Group which will work to identify and develop the most effective cancer-directed immunotherapy treatments for Head and Neck cancers. Read the full press release HERE.
Cancer MoonShot 2020 announced the formation of the Breast Cancer Working Group which will work to identify and develop the most effective cancer-directed immunotherapy treatments for breast cancer.Read More
Dr. Patrick Soon-Shiong CEO of NantWorks and founder of Cancer Moonshot 2020, announced that a novel genetically engineered adenovirus vaccine designed to treat colon cancer showed, in Phase II testing, a more than doubling of survival rate, with little to no toxicity. Promising results show some patients alive now more than five years after receiving the colon vaccine while on no other therapy.